|
||
| |||||||
|
New NK1 antagonists from Merck The tachykinins were first identified in 1931 however the therapeutic potential of their receptor antagonists is only starting to be realized. Furthest advanced is the development of NK1 antagonists for the treatment of anxiety/depression, emesis and certain types of pain, however tachykinin receptor antagonists have been strongly implicated for the treatment of at least 6 major disease groups. In addition to CNS disorders, pain and emesis, tachykinin receptor antagonists have also shown promise for the treatment of airway disease, urinary incontinence and intestinal disfunction. We recently published an overview of this field (Click here for access information). At the time of this analysis, the lead NK1 antagonist was MK869 which has been assessed in phase II studies and demonstrated to be an effective anti-emetic and anti-depressent. Merck press releases, have however stated that further development for depression would be put on hold awaiting follow-up molecules. In is therefore of interest that Merck researchers recently published preclinical data describing a novel high affinity, orally active, NK1 receptor antagonist with a long central duration of action. Further development is expected. Projects such as these are overviewed in full DiscoveryDossiers. DiscoveryDossiers ~ TherapeuticsAdvances ~ PharmaceuticalSolutions ~ LeadDiscovery ~ Purchase DiscoveryDossiersLeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
| ||||||||
